Drug-Eluting Stents: A Review of the Current Literature

Cardiology in Review

Volumn 12, Issue 1, 2004, Pages 37-43

  Laroia, Sandeep T ^a,b   Laroia, Archana T ^a  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

^b NONE   (United States)

Author keywords

Coronary artery disease; Coronary interventions; Drug eluting stents; Stents

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; TICLOPIDINE;

ANGIOCARDIOGRAPHY; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ELUTING STENT; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; PHYSICIAN; RESTENOSIS; REVIEW; SLOW RELEASE FORMULATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; DRUG DELIVERY SYSTEMS; HUMANS; PACLITAXEL; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS;

EID: 0346880306     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000090893.66550.9d     Document Type: Review

References (22)

1. Curfman GD. Sirolimus-eluting coronary stents. N Engl J Med. 2002;346:1770-1771.
2. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701-706.
3. Serruys PW, Jaegere PD, Kiemenij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in-patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
4. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
5. Marcotty J. A tiny world-changer. Star Tribune. 2003; April 25:D1-D2.
6. Medical Services Advisory Committee (MSAC). Coated stents for coronary arteries. Horizon scanning briefing No. 2, 2002. Available at: www. msac.gov.au. Accessed June 15, 2003.
7. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999;341:318-327.
8. Gerschlick AH, Baron J. Dealing with in-stent restenosis. Heart. 1998;79:319-323.
9. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872-1878.
10. Raizner AE, Oesterle SW, Waksman R, et al. Inhibition of restenosis with beta-emitting radiotherapy: report of the proliferation reduction with vascular energy trial (PREVENT). Circulation. 2000;102:951-958.
11. Jenkins NP, Prendergast BD, Thomas M. Drug-eluting coronary stents. BMJ. 2002;325:1315-1316.
12. Colombo A on behalf of the TAXUS II Investigators. TAUXS II: 12-month results. Presented at the European Paris Course on Revascularization (EuroPCR), Paris, 2003. Available at: www.tctmd.com. Accessed June 13, 2003.
13. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
14. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
15. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
16. Moses JW, Leon MB, Popma JJ, et al. for the SIRIUS Investigators. A US multicenter, randomized, double blind study of the SIRolimUS-eluting stent in de novo native coronary lesions. Presented at Transcatheter Cardiovascular Therapeutics (TCT), Washington DC, 2002. Available at: www. tctmd.com. Accessed June 13, 2003.
17. de la Fuente LM, Miano J, Mrad J, et al. Initial results of the Quantum drug-eluting stent (QuaDSQP-2) Registry (BARDDS) in human subjects. Catheter Cardiovasc Interv. 2001;53:480-488.
18. Sousa SE. 3-year follow-up of the First-In-Man patients: are there any late concerns? Presented at the CRF drug-eluting stent (DES) symposium at the American College of Cardiology (ACC) 52nd scientific sessions, Chicago, 2003. Available at: www. tctmd.com (Class C). Accessed June 13, 2003.
19. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 2002;106:1610-1613.
20. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation. 2003;107:381-383.
21. Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with a sirolimus-eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J. 2001;22:2125-2130.
22. Degertekin M, Regar E, Tanabe K, et al. Evaluation of coronary remodeling after sirolimus-eluting stent implantation by serial three-dimensional intravascular ultrasound. Am J Cardiol. 2003;91:1046-1050.